Company* (Country;

Product Area

Details (Date)

Adherex Technologies Inc. (Canada; TSE:AHX)

Cadherin Biomedical Inc.*

Adherex agreed to acquire noncancer cadherin-based intellectual property from CBI

Adherex will pay $1M by issuing up to 2.2M shares of stock, and a royalty rate of 2%; the deal requires approval from CBI shareholders (12/10)

Aeres Biomedical Ltd.* (UK)

Peregrine Pharmaceuticals Inc. (PPHM)

Agreement under which Aeres will humanize a vascular-targeting antibody

Peregrine will provide a murine antibody for humanization by Aeres; terms were not disclosed (12/11)

Affymetrix Inc. (AFFX)

NuGEN Technologies Inc.*

Collaboration to develop NuGEN's Whole Transcript Amplification system for use with Affymetrix GeneChip technology

They intend to develop a new target amplification method to support the next generation of GeneChip arrays; terms were not disclosed (12/10)

Affymetrix Inc. (AFFX)

Arcturus Bioscience Inc.*

Collaboration to develop tools for gene expression analysis on paraffin-embedded clinical biopsy samples

The companies will use Paradise reagents from Arcturus with a new custom array from Affymetrix (12/4)

Agenix Ltd. (Australia; ASX:AGX)

Biosite Inc. (BSTE)

License agreement under which Biosite licensed rights to D-dimer

Biosite intends to incorporate the 3B6 antibody from AGEN, a subsidiary, of Agenix, specific for D-dimer, into a diagnostic to identify causes of shortness of breath; terms were not disclosed (11/26)

Alexion Pharmaceuticals Inc. (ALXN)


Collaboration for development of a human c-MPL agonist antibody to treat chemotherapy-induced thrombocytopenia; Alexion discovered the preclinical compound

The companies will jointly develop and commercialize the compound, sharing expenses and revenues on a 70-30 split, with Alexion having the larger share; Alexion gets initial payments and a potential milestone, and XOMA is entitled to royalties and milestones (12/18)

Archemix Corp.*

Regado Biosciences*

License agreement granting Regado rights to develop antidote-controlled aptamer therapeutics

The license relates to Archemix's SELEX patent portfolio; Regado is using the technology to develop drugs for thrombosis (11/17)

Avalon Pharmaceuticals Inc.*

Medarex Inc. (MEDX)

Collaboration on development of antibody products using Avalon targets and Medarex technology

The companies will shares the costs and responsibilities of development, and jointly commercialize resulting products (10/30)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Peregrine Pharmaceuticals Inc. (PPHM)

License agreement for an antibody Avanir produced for a cancer target in Peregrine's vascular-targeting program

Avanir received a license fee and could get a milestone payment along with royalties on sales; terms were not disclosed (12/10)

Bavarian Nordic A/S* (Denmark)

Pharmexa A/S* (Denmark)

Collaboration to test Bavarian's MVA-BN vector technology in combination with Pharmexa's HER-2 DNA AutoVac vaccine

The companies expect to start Phase I/II trials in 18 months in that program, and test other combinations in breast cancer patients; terms were not disclosed (10/30)

Berna Biotech Ltd. (Switzerland; SWX:BBIN)

Dynavax Technologies Corp.*

License and supply agreement under which Dynavax gets worldwide, nonexclusive rights to use Berna's hepatitis B surface antigen, HBsAg

Dyanavax will incorporate the technology in ISS development programs targeting HBV; Berna will supply the antigen and Dynavax will commercialize resulting products exclusively; terms were not disclosed (11/3)

Biogen Idec Inc. (BIIB)

Therion Biologics Corp.*

Therion licensed patent rights relating to lymphocyte function associated with antigen-3

Therion got a nonexclusive license for oncology products incorporating the LFA-3 co-stimulatory molecule; Therion is paying an up-front fee and potential milestones and royalties (12/15)

Bruker Daltonics Inc. (unit of Bruker Biosciences Corp; BRKR)

SurroMed Inc.*

Parternship that includes purchase of Bruker mass spectrometers for use by SurroMed

The deal includes a collaboration on development of software and sample fractionation products; terms were not disclosed (12/1)

CeMines Inc.*

Chemicon International Inc. (unit of Serologicals Corp; SERO)

Exclusive five-year licensing agreement under which Chemicon has access to 170 CeMines antibodies

Chemicon will use the antibodies to broaden its offering of transcription factor reagents for cancer and cell biology researchers; Chemicon has an option to get access to additional antibodies for the life of the deal; terms were not disclosed (10/30)

Chemical Diversity Labs Inc.*

ESBATech AG* (Switzerland)

CDL is supplying ESBATech a maximally diverse library for screening

ESBATech will screen the library in its yeast-based system and the University of Zurich will use an in silico approach; terms were not disclosed (12/15)

Chemical Diversity Labs Inc.*

Sienabiotech SpA* (Italy)

Research collaboration under which Sienabiotech will screen the aspartyl protease-focused library provided by CDL

Terms of the deal were not disclosed (12/2)

Chiron Corp. (CHIR)

Vertex Pharmaceuticals Inc. (VRTX)

Vertex licensed nonexclusive rights to research and develop drugs against certain hepatitis C targets

Also, Chiron was granted limited rights to review Vertex's HCV drug VX-950 for potential licensing; the companies settled patent litigation initiated by Chiron in the area of hepatitis C technology; terms of the various deals were not disclosed (11/7)

Chiron Corp. (CHIR)

Rigel Pharmaceuticals Inc. (RIGL)

Rigel licensed nonexclusive rights to discover and develop small-molecule therapeutics against certain hepatitis C targets

Financial and other terms of the deal were not disclosed (11/3)

Collegium Pharmaceuticals Inc.*

Endo Pharmaceuticals Inc. (ENDP)

Development and licensing deal for pain products with abuse- deterrent properties

Collegium will apply its DETERx technology for new fomulations of drugs; Endo is making an up-front payment and will pay milestones and royalties if a product results (12/3)

Coley Pharmaceutical Group Inc.*

Chiron Corp. (CHIR)

Chiron licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccine candidates

Chiron got nonexclusive rights to use the CpG adjuvant in infectious disease vaccines in exchange for up-front license fees and development milestones, as well as royalties on sales (12/23)

CPEC Ltd. (venture of Incara Pharmaceuticals Corp.: INCR; and Indevus Pharmaceuticals Inc.: IDEV)

ARCA Discovery Inc.*

ARCA licensed the beta-blocker bucindolol; the drug's development in heart failure was stopped in 1999

ARCA licensed the drug after examining trial data and noting a genetic marker that correlates with nonresponders; it would pay CPEC milestones and royalty payments (11/21)

Crucell NV (the Netherlands; CRXL)

Progenics Pharmaceuticals Inc. (PGNX)

Crucell will develop a cell line for production of a recombinant protein for Progenics

The deal involves Crucell's PER.C6 technology; Crucell is eligible for undisclosed milestone payments (12/8)

Cytopia Pty. Ltd. (Australia; subsidiary of Medica Holdings Ltd.)

Myomatrix Therapeutics LLC

Collaboration on developing drugs to treat cardiovascular disorders by inhibiting a kinase target

Each company has technology in the area; they will jointly fund the research program, first targeting an orphan disease, then heart disease and hypertension (12/15)

Cyto Pulse Sciences Inc.*

Medarex Inc. (MEDX)

Agreement giving Medarex certain exclusive rights to use Cyto Pulse's electrofusion technology to derive hybridomas for generating human antibody producing cells

The hybridomas will be derived from the Medarex UltiMAb System; terms of the deal were not disclosed (12/18)

Dharmacon Inc.*

Akceli Inc.*

Research collaboration to study combination of Dharmacon's siRNA-mediated gene silencing and Akceli's whole-cell reverse transfection

Akceli will carry out experiments, and the companies will use results to improve their products; they also intend to develop improved methods for transfection optimization (11/3)

DiagnoCure Pharmaceuticals Inc.*

Gen-Probe Inc. (GPRO)

License and collaboration deal in which they will develop a urine test to detect a new genetic marker for prostate cancer

Gen-Probe would market the test that detects the PCA3 gene; Gen-Probe is paying $3M up front and up to $7.5M over three years, and DiagnoCure would get royalties of 8% or 16%, depending on sales levels (11/20)

Feminique Corp. (OTC BB:FEMQQ)

Targent Inc.*

Targent acquired an oral cytotoxic drug, dibromodulcitol, from Feminique

Terms were not disclosed (12/11)

Genaissance Inc. (GNSC)

Sciona Ltd.* (UK)

Genaissance licensed its HAP technology to support product development work at Sciona

Genaissance is getting a 30% stake in Sciona as part of the deal, and would get royalties on sales related to its technology (11/18)

Genome BioSciences Inc.*

Chemicon International Inc. (division of Serologicals Corp.; SERO)

Exclusive license agreement for Genome BioSciences' Positive-Positive Selection gene targeting technology

Chemicon gained exclusive rights to use the technology for generating genetically modified cell lines and mice and to sub- license the technology; terms were not disclosed (11/18)

GlycoFi Inc.*

Biogen Idec Inc. (BIIB)

Joint research study to evaluate GlycoFi's humanized yeast platform for production of an undisclosed Biogen Idec protein

Biogen Idec will provide support for the study of GlycoFi's expression technology to pro- duce glycoproteins; terms were not disclosed (11/10)

Hemosol Inc. (Canada; HMSL)

ProMetic Life Sciences Inc. (Canada; TSE:PLI)

Hemosol in-licensed plasma separation technology developed by ProMetic and the American Red Cross

Hemosol gained a North American license to Cascade technology in exchange for 2M shares of stock and license fees of $16.5M over four years (12/4)

Icon Genetics AG* (Germany)

Novoplant GmbH* (Germany)

License agreement giving Novoplant access to Icon's Transgene Operating Systems for manufacturing immune-response proteins in plants

The license is expected to help Novoplant develop products for animal health; terms were not disclosed (11/13)

Ingenium Pharmaceuticals AG* (Germany)

Molecular Engines Laboratories SA* (France)

Agreement under which MEL gets access to Ingenium's genetic mouse model related to tumor reversion

MEL gets exclusive rights to the technology on the TSAP6 model; terms were not disclosed (10/28)

Ingenuity Systems*

SurroMed Inc.*

License to Ingenuity's Pathway Analysis application for biological research

Terms were not disclosed (12/8)


Pierce Biotechnology Inc.*

License to "Smith" patent for supply of research reagents and products

Pierce licensed rights to the fusion protein purification technique; terms were not disclosed (10/29)

Interleukin Genetics Inc. (OTC BB:ILGN)

Molecular SkinCare Ltd.* (UK)

Interleukin granted Molecular SkinCare and Asterion Ltd. rights to undisclosed technology

Interleukin gained a 5% equity stake in Molecular SkinCare as part of the deal; Asterion is an affilate of the University of Sheffield, which had licensed the technology to Interleukin (11/4)

Kalypsys Inc.*

CV Therapeutics Inc. (CVTX)

Collaboration to develop drugs for cardiovascular diseases

CV is providing assays and Kalypsys is developing screens and will optimize leads; Kalypsys is getting undisclosed up-front, research and equity funding; it also could get milestone payments and has an option to co-fund and co-develop resulting drugs (11/17)

KuDOS Pharmaceuticals* (UK)

Novacea Inc.*

Novacea licensed from KuDOS North American rights to AQ4N, a hypoxic cell-activated agent for cancer

Novacea gained rights in all indications in exchange for undisclosed milestone and royalty payments; companies will work together to coordinate worldwide development (12/11)

MacroGenics Inc.*

Genzyme Corp. (GENZ)

Partnership to develop therapies for immune-mediated diseases

They will work to advance MacroGenics' preclinical program targeting the Fc receptor CD16; Genzyme is making a $5M equity investment in MacroGenics, and the companies will jointly fund the program and split resulting profits (10/29)

Maxim Pharmaceuticals Inc. (MAXM)

Myriad Genetics Inc. (MYGN)

License deal under which Myriad gets exclusive rights to the MX90745 series of apoptosis- inducing compounds for cancer

Maxim will receive up to $27M in license fees, research support and milestone payments, as well as royalties on any sales (12/2)

Micrologix Biotech Inc. (Canada; TSE:MBI)

Spring Bank Technologies Inc.*

Spring Bank licensed worldwide rights to MBI-1313, a nucleotide analogue being developed for hepatitis B virus infections

Micrologix will get up to $3.5M in milestone payments, royalties on sales and an equity position in Spring Bank; Spring Bank got a $2.6M grant from the NIH as part of the deal to advance the compound (12/9)

Miikana Therapeutics Inc.*

NovImmune SA* (Switzerland)

Collaboration to develop fully human antibody-based drugs for cancer and immune diseases

The companies are combining efforts in a 50-50 sharing of costs and profits, using Miikana's targets and NovImmune's antibody expertise (10/4)

Mixture Sciences Inc.*

Mpex Pharmaceuticals Inc.*

Research collaboration using Mixture's combinatorial libraries to identify antibacterial compounds for Mpex to develop

Terms were not disclosed (11/20)

Molecular Probes Inc. (subsidiary of Invitrogen Corp.; IVGN)

Chemicon International Inc. (unit of Serologicals Corp; SERO)

Licensing agreement under which Chemicon gets rights to fluorophores for labeling biologically active molecules

The deal includes Alexa Fluor and tandem conjugate technologies from Molecular Probes; terms were not disclosed (10/29)

Neose Technologies Inc. (NTEC) (Germany)

Rentschler Biotechnologie GmbH & Co. KG* material

Collaboration under which Neose will develop a therapeutic protein using Rentschler

Rentschler has an option to co-develop the resulting protein; terms were not disclosed (10/27)

Onyx Pharmaceuticals Inc. (ONXX)

Sangamo BioScience Inc. (SGMO)

Sangamo licensed rights to Onyx's oncolytic adenovirus vector technology

Sangamo got worldwide exclusive rights to all therapeutics using an armed therapeutic virus that encodes a zinc finger DNA-binding protein transcription factor; Onxy is eligible to receive milestone and royalty payments (12/17)

Orphan Medical Inc. (ORPH)

Celltech Group plc (UK; LSE:CCH)

License for European rights to Orphan Medical's Xyrem

Celltech plans to file for approval of Xyrem for cataplexy in early 2004; Celltech paid $2.5M up front and could pay up to $13M in development and sales milestones, as well as royalties on sales (10/30)

Plexxikon Inc.*

Phenomix Corp.*

Collaboration to develop a series of small molecules that inhibit the protein kinase c-Kit for treating various diseases

Plexxikon will apply its discovery platform to create inhibitors, and Phenomix will evaluate the leads; they can develop resulting products alone or jointly, and intend to partner product candidates (11/20)

PreAnalytiX GmbH (Switzerland; venture of Qiagen NV and Becton, Dickinson & Co.)

Affymetrix Inc. (AFFX)

Collaboration to optimize the PreAnalytiX PAXgene Blood RNA System for use with Affymetrix GeneChip microarray technology

A goal is to improve gene expression profile results on RNA extracted from whole blood (10/31)

Qiagen NV (the Netherlands; QGENF)

Artus GmbH* (Germany)

Agreement under which Artus will integrate Qiagen's nucleic acid sample preparation products in its diagnostic systems

The products will be used in the detection of various infectious diseases; terms were not disclosed (12/10)

Qiagen NV (the Netherlands; QGENF)

Affymetrix Inc. (AFFX)

Collaboration to optimize Qiagen siRNA-mediated gene silencing using Affymetrix GeneChip microarray technology

The goal is to develop procedures that can be standarized to analyze effects on a genome-wide basis (10/31)

Scancell Ltd.* (UK)

Onyvax Ltd.* (UK)

Agreement on development of Scancell's ImmunoBody cancer vaccine technology

As part of the deal, Onyvax got a non-exclusive license to develop the technology; details were not disclosed (12/12)

Scynexis Europe Ltd.* (UK)

GeneCare Research Institute Co. Ltd.* (Japan)

Scynexis will provide a range of services to support development of anti-inflammatory drugs by GeneCare

Scynexis' HEOS system will be used to develop high-purity compound libraries for GeneCare; terms were not disclosed (12/8)

SemBioSys Genetics Inc.* (Canada)

Martek Biosciences Corp. (MRTK)

Agreement to co-develop value-added specialty oil products with pharmaceutical and nutraceutical applications

SemBioSys will use its technologies to develop plant-based DHA products for Martek in exchange for up to $10M in research and milestone payments, as well as royalties on product sales (12/17)

Structural GenomiX Inc.*

UroGene SA* (France)

Collaboration for discovery and development of drugs for urological cancers

Companies will jointly develop small-molecule inhibitors; SGX would have rights to resulting products in North America and UroGene in Europe (12/16)

3rd Millennium Inc.*

CytRx Corp. (CYTR)

Partnership to implement a computing platform for RNAi- based development programs focused on Type II diabetes and obesity

CytRx subsidiary Araios Inc. will use the system to generate libraries of compounds targeting those diseases; terms were not disclosed (11/21)

Tripos Inc. (TRPS)

Biovitrum AB* (Sweden)

Research program to develop software enabling improved tools for drug discovery

The informatics project is to enhance the GASP software tool; terms were not disclosed (12/8)

YM BioSciences Inc. (Canada; TSE:YM)

Oncoscience AG* (Germany)

Oncoscience licensed European rights to cancer drug TheraCIM hR3, an EGFR antibody

YM will receive at least $30M as a share of sublicensing fees and as a premium royalty on initial sales, as well as a royalty on sales (11/12)


# This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange.